Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How Gilead Intends To Deliver On Promise Of Remdesivir For COVID-19

Executive Summary

When the coronavirus hit China, Gilead only had enough remdesivir for 5,000 patients. Here’s how it went about expanding production.

You may also be interested in...



A Pandemic Template For Swift Approval? Veklury Stability Questions Deferred For Later Study

The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.

US COVID Antibody Drug Supply: Regeneron, Lilly, AstraZeneca To Contribute To 1M Dose Goal For 2020

Precise amounts to be supplied by each company will depend in part on whether the monoclonal antibody drugs are used for prevention or treatment because dosage strengths will be different.

HHS Shifts Remdesivir Distribution To Gilead As Supply Crunch Eases

AmerisourceBergen will continue to serve as the sole US distributor of Veklury (remdesivir) through the end of this year and will continue to sell the the COVID-19 treatment directly to hospitals.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS142163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel